Amylin Pharmaceuticals Inc - Current report filing (8-K)
June 19 2008 - 4:08PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13
or 15(d) of
the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported):
June 16, 2008
AMYLIN PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or Other
Jurisdiction of
Incorporation)
|
|
0-19700
(Commission File Number)
|
|
33-0266089
(I.R.S. Employer Identification No.)
|
9360 Towne Centre Drive
San Diego, California 92121
(Address of principal executive offices and zip code)
Registrants telephone number, including area
code:
(858)
552-2200
Check the
appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (
see
General
Instruction A.2. below):
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CRF 240.13e-4(c))
Item 1.01. Entry into a Material
Definitive Agreement.
On June 16, 2008, Amylin Pharmaceuticals, Inc.
and Mallinckrodt Inc. entered into an Amendment to their Exenatide
Manufacturing Agreement, or the Amendment, which amends the manufacturing agreement
between the parties, dated October 1, 2003, pursuant to which Mallinckrodt
manufactures and supplies to Amylin bulk exenatide, the active ingredient in
BYETTA® (exenatide) injection. Under the
terms of the Amendment, the termination date of agreement has been extended for
a period of four years to September 30, 2012.
2
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, as amended, the registrant
has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
AMYLIN
PHARMACEUTICALS, INC.
|
|
|
|
|
Dated: June 19, 2008
|
By:
|
/s/
LLOYD A. ROWLAND
|
|
|
Lloyd A. Rowland
|
|
|
Vice
President, Governance and Compliance, and
Secretary
|
3
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024